TY - JOUR
T1 - Self-Assembled Reduced Albumin and Glycol Chitosan Nanoparticles for Paclitaxel Delivery
AU - Razi, Muhamad Alif
AU - Wakabayashi, Rie
AU - Goto, Masahiro
AU - Kamiya, Noriho
N1 - Funding Information:
This research was funded by the Japan Society for the Promotion of Science (JSPS) and KAKENHI Grants JP16H04581 and JP16H06369 from the Ministry of Education, Culture, Sports, Science and Technology (MEXT). M.A.R. was supported by a scholarship from MEXT (Scholarship 150043). The authors thank Sarah Dodds from the Edanz Group for editing a draft of the manuscript.
Publisher Copyright:
Copyright © 2019 American Chemical Society.
PY - 2019/2/19
Y1 - 2019/2/19
N2 - Cancer continues to pose health problems for people all over the world. Nanoparticles (NPs) have emerged as a promising platform for effective cancer chemotherapy. NPs formed by the assembly of proteins and chitosan (CH) through noncovalent interactions are attracting a great deal of interest. However, the poor water solubility of CH and low stability of this kind of NP limit its practical application. Herein, the formation of reduced bovine serum albumin (rBSA) and glycol chitosan (GC) nanoparticles (rBG-NPs) stabilized by hydrophobic interactions and disulfide bonds was demonstrated for paclitaxel (PTX) delivery. The effects of the rBSA:GC mass ratio and pH on the particle size, polydispersity index (PDI), number of particles, and surface charge were evaluated. The formation mechanism and stability of the NPs were determined by compositional analysis and dynamic light scattering. Hydrophobic and electrostatic interactions were the driving forces for the formation of the rBG-NPs, and the NPs were stable under physiological conditions. PTX was successfully encapsulated into rBG-NPs with a high encapsulation efficiency (90%). PTX-loaded rBG-NPs had a particle size of 400 nm with a low PDI (0.2) and positive charge. rBG-NPs could be internalized by HeLa cells, possibly via endocytosis. An in vitro cytotoxicity study revealed that PTX-loaded rBG-NPs had anticancer activity that was lower than that of a Taxol-like formulation at 24 h but had similar activity at 48 h, possibly because of the slow release of PTX into the cells. Our study suggests that rBG-NPs could be used as a potential nanocarrier for hydrophobic drugs.
AB - Cancer continues to pose health problems for people all over the world. Nanoparticles (NPs) have emerged as a promising platform for effective cancer chemotherapy. NPs formed by the assembly of proteins and chitosan (CH) through noncovalent interactions are attracting a great deal of interest. However, the poor water solubility of CH and low stability of this kind of NP limit its practical application. Herein, the formation of reduced bovine serum albumin (rBSA) and glycol chitosan (GC) nanoparticles (rBG-NPs) stabilized by hydrophobic interactions and disulfide bonds was demonstrated for paclitaxel (PTX) delivery. The effects of the rBSA:GC mass ratio and pH on the particle size, polydispersity index (PDI), number of particles, and surface charge were evaluated. The formation mechanism and stability of the NPs were determined by compositional analysis and dynamic light scattering. Hydrophobic and electrostatic interactions were the driving forces for the formation of the rBG-NPs, and the NPs were stable under physiological conditions. PTX was successfully encapsulated into rBG-NPs with a high encapsulation efficiency (90%). PTX-loaded rBG-NPs had a particle size of 400 nm with a low PDI (0.2) and positive charge. rBG-NPs could be internalized by HeLa cells, possibly via endocytosis. An in vitro cytotoxicity study revealed that PTX-loaded rBG-NPs had anticancer activity that was lower than that of a Taxol-like formulation at 24 h but had similar activity at 48 h, possibly because of the slow release of PTX into the cells. Our study suggests that rBG-NPs could be used as a potential nanocarrier for hydrophobic drugs.
UR - http://www.scopus.com/inward/record.url?scp=85061556691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061556691&partnerID=8YFLogxK
U2 - 10.1021/acs.langmuir.8b02809
DO - 10.1021/acs.langmuir.8b02809
M3 - Article
C2 - 30673276
AN - SCOPUS:85061556691
SN - 0743-7463
VL - 35
SP - 2610
EP - 2618
JO - Langmuir
JF - Langmuir
IS - 7
ER -